All articles
527 evidence-based articles, checked against primary sources.
Supplements
Libido Supplements for Women: Do Any Actually Work?
Low libido in women is usually multifactorial, so a pill rarely fixes it. We grade the popular supplements plainly, flag the FDA's warnings on tainted sexual-enhancement products, and point to what actually has evidence.
July 17, 2026 7 min
Supplements
Lion's Mane: What the Brain-Health Evidence Shows
Lion's mane is one of the most-hyped brain supplements online. Here's what the small human trials actually show for memory, focus and mood — and the midlife brain-fog causes worth ruling out first.
July 17, 2026 7 min
Nutrition & Diet
Histamine Intolerance: What the Evidence Really Says
Histamine intolerance is everywhere online, but the diagnosis is far from settled. We grade the evidence honestly — no reliable test, heavy symptom overlap, and a genuine estrogen connection — and explain how a safe, time-limited trial actually works.
July 17, 2026 8 min
Mental Health
ADHD in Women: Why It's So Often Missed
Why ADHD is so often missed in women and girls, how it really presents, the honest evidence on the perimenopause hormone link, and how to seek a proper evaluation.
July 17, 2026 7 min
Supplements
Best Magnesium Supplements: How to Choose (2026)
A buyer's guide to choosing a quality magnesium supplement: match the form to your goal (glycinate, citrate, oxide, malate, threonate — graded honestly), then screen for USP or NSF third-party testing, elemental-magnesium labeling, no proprietary blends, and a safe dose within the 350 mg supplemental ceiling. Includes registry-verified certified examples and who should be cautious.
July 17, 2026 7 min
Weight & Metabolism
Survodutide: A GLP-1/Glucagon Drug for Weight and Liver
What survodutide is, how its dual GLP-1/glucagon action targets both weight and the liver, what mid-stage and early phase 3 trials actually showed, and why it remains investigational and not prescribable.
July 17, 2026 7 min
Weight & Metabolism
GLP-1 Medications: The Complete Honest Guide
GLP-1 drugs mimic a gut hormone to curb appetite and steady blood sugar. This hub explains the FDA-approved options, who qualifies, real trial results, cost and coverage, side effects, and what women in midlife specifically need to know — then routes you to the right deep dive.
July 17, 2026 7 min
Weight & Metabolism
GLP-1 Weight-Loss Timeline: What to Expect Month by Month
GLP-1 weight loss is a year-plus arc, not a quick fix. Here's what really happens month by month — appetite changes, dose step-ups, when most weight lands, why the plateau is normal, and what the trials show about stopping.
July 17, 2026 8 min
Weight & Metabolism
Mazdutide: The GLP-1/Glucagon Dual Agonist to Watch
Mazdutide is a once-weekly GLP-1 and glucagon receptor dual agonist, approved for weight management in China in 2025 but investigational and unavailable in the US. Here's the verified trial evidence, its standout liver-fat signal, and what it may mean for midlife metabolic health.
July 17, 2026 7 min
Weight & Metabolism
The 2026 GLP-1 Coverage Report: Who Pays, Where
As of January 2026, about 13 state Medicaid programs cover GLP-1 drugs for obesity while nearly all cover them for type 2 diabetes. Roughly 80% of adult Medicaid enrollees live in states with no obesity pathway. Medicare is barred by law from covering obesity-only drugs. This citable report pulls together the KFF, CMS, and FDA figures behind the 2026 coverage map.
July 17, 2026 6 min
Weight & Metabolism
CagriSema: What the Trials Show So Far
CagriSema pairs cagrilintide (an amylin analog) with semaglutide (a GLP-1) in one weekly injection. Here is the honest picture: what it is, where it stands with the FDA, what the REDEFINE trials actually showed, and how it compares with tirzepatide — without the hype.
July 17, 2026 7 min
Gynecologic & Reproductive Health
Do GLP-1s Affect Birth Control? Tirzepatide vs the Rest
Tirzepatide's FDA label warns it can make oral birth control less effective; semaglutide's does not. We break down why, which methods are unaffected, and what the labels actually advise — without telling you to start or stop anything.
July 17, 2026 7 min
PCOS
GLP-1s for PCOS: Evidence, Off-Label Use, and Cautions
No GLP-1 is FDA-approved for PCOS — its use is off-label. Weight loss is the best-documented benefit; effects on cycles, ovulation, and hormones are still emerging. Plus the fertility and contraception cautions every woman should know.
July 17, 2026 7 min
Bone Health
GLP-1s and Bone Density: Should Midlife Women Worry?
The theoretical worry is real, but the trial data so far are reassuring — and the practical answer is the same plan that protects your muscle.
July 17, 2026 7 min
Weight & Metabolism
GLP-1 Microdosing: What It Is and Why Experts Are Wary
GLP-1 “microdosing” means deliberately taking doses far below the approved range, usually from compounded vials. It is not an FDA-recognized or studied approach, and experts are wary because sub-therapeutic, self-measured dosing raises real risks without proven benefit.
July 17, 2026 8 min
Weight & Metabolism
GLP-1s and Alcohol: Safety, Side Effects, and the Craving Research
Is it safe to drink alcohol on a GLP-1 like Ozempic, Wegovy, or Zepbound? An honest, evidence-graded look at side effects, blood-sugar risk, contraception, and the semaglutide-alcohol craving trials.
July 17, 2026 8 min
Weight & Metabolism
Ozempic Side Effects in Women: What's Different
Ozempic's main side effects (nausea, vomiting, diarrhea, plus rare pancreatitis, gallbladder disease and a rodent-based thyroid boxed warning) don't differ by sex. What is genuinely women-specific is downstream of rapid weight loss and returning fertility: unexpected pregnancy, PCOS and cycle changes, facial volume loss, temporary hair shedding, and muscle and bone loss that hit midlife women harder. Here is the honest, evidence-graded version — with the tirzepatide-versus-semaglutide contraception facts that most articles get wrong.
July 17, 2026 9 min
Weight & Metabolism
Does Medicaid Cover GLP-1s? State-by-State (2026)
Medicaid coverage of GLP-1s splits sharply: broad for type 2 diabetes, limited and state-dependent for obesity. We give the verified January 2026 picture from KFF and teach you to confirm your own state's coverage instead of trusting a grid that goes stale.
July 17, 2026 7 min